Cotellic (Cobimetinib Fumarate) Patent Expiration, LOE Window & CMS Spending

Cotellic (Cobimetinib Fumarate) by Roche / Genentech: FDA Orange Book core substance LOE 2036-12-30, 0 AB generics, $10.5M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorRoche / Genentech
FDA Application & PathwayN206192 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2036-12-30
Last Listed Patent or Exclusivity Date2036-12-30
Orange Book Patents (*PED Extensions)13 patents (6 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$10.5M
2024 Medicare Part D Spend$8.2M
2024 Medicaid Spend$2.4M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Roche / Genentech across sibling Meru public-data platforms.